The use of methotrexate for treatment of inflammatory bowel disease in clinical practice

Digestive and Liver Disease

Volumn 44, Issue 2, 2012, Pages 123-127

  Saibeni, Simone ^a   Bollani, Simona ^a   Losco, Alessandra ^b   Michielan, Andrea ^c   Sostegni, Raffaello ^d   Devani, Massimo ^e   Lupinacci, Guido ^f   Pirola, Lorena ^g   Cucino, Claudia ^h   Meucci, Gianmichele ⁱ   Basilisco, Guido ^j   D'Incà, Renata ^c   Bruno, Savino ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e RHO HOSPITAL   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h ISTITUTO CLINICO CITTÀ STUDI   (Italy)

ⁱ San Giuseppe Hospital   (Italy)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

Crohn's disease; Methotrexate; Therapy; Ulcerative colitis

Indexed keywords

FOLIC ACID; MERCAPTOPURINE; METHOTREXATE;

ADULT; ALOPECIA; ARTICLE; ASTHENIA; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BONE MARROW TOXICITY; CLINICAL PRACTICE; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; ULCERATIVE COLITIS; VOMITING;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855735860     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.09.015     Document Type: Article

References (26)

1. Cutolo M., Sulli A., Pizzorni C., et al. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001, 60:729-735.
2. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999, 11:226-232.
3. Fraser A.G. Methotrexate: first or second-line immunomodulator?. Eur J Gastroenterol Hepatol 2003, 15:225-231.
4. Feagan B.G., Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 2004, 33:407-420.
5. Siegel C.A., Sands B.E. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005, 22:1-16.
6. Kozarek R.A., Patterson D.J., Gelfand M.D., et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356.
7. Feagan B.G., Rochon J., Fedorak R.N., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332:292-297.
8. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000, 342:1627-1632.
9. Hausmann J., Zabel K., Herrmann E., et al. Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010, 16:1195-1202.
10. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
11. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62. European Crohn's and Colitis Organisation (ECCO).
12. Meuwissen S.G., Ewe K., Gassull M.A., et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000, 12:13-18.
13. Herfarth H.H., Osterman M.T., Isaacs K.L., Lewis J.D., Sands B.E. Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis 2010, 16:1421-1430.
14. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008, 2:24-62. European Crohn's and Colitis Organisation (ECCO).
15. Satsangi J., Silverberg M.S., Vermeire S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
16. Orlando A., Armuzzi A., Papi C., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011, 43:1-20.
17. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
18. Wahed M., Louis-Auguste J.R., Baxter L.M., et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009, 30:614-620.
19. Din S., Dahele A., Fennel J., et al. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis 2008, 14:756-762.
20. Nathan D.M., Iser J.H., Gibson P.R. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008, 23:954-958.
21. Domènech E., Mañosa M., Navarro M., et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008, 42:395-399.
22. Lémann M., Zenjari T., Bouhnik Y., et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95:1730-1734.
23. Chong R.Y., Hanauer S.B., Cohen R.D. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001, 15:35-44.
24. Prey S., Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009, 160:622-628.
25. Ruemmele F.M. Immunomodulation with methotrexate: underused and undervalued?. Dig Dis 2009, 27:312-314.
26. Fournier M.R., Klein J., Minuk G.Y., et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol 2010, 105:1620-1626.